Clinical efficacy and changes of serum VEGF-A,VEGF-B,and PLGF after conbercept treating neovascular agerelated macular degeneration  

作　　者：Xiao-Dong Chen Chan Li Guo-Long Ding Yan Suo Yu-Sheng Zhu Hui-Qin Lu 

机构地区：[1]Department of Ophthalmology,Xi’an No.1 Hospital,Xi’an 710002,Shaanxi Province,China [2]First Affiliated Hospital of Northwest University,Northwest University,Xi’an 710002,Shaanxi Province,China [3]Shaanxi Institute of Ophthalmology,Xi’an 710002,Shaanxi Province,China

出　　处：《International Journal of Ophthalmology(English edition)》2023年第9期1489-1494,共6页国际眼科杂志（英文版）

基　　金：Supported by the Bethune Lumitin Research Funding for the young and middle-aged Ophthalmologists,China(No.BJ-LM202009);Shaanxi Province Key Research and Development Project,China(No.2022SF-312).

摘　　要：AIM:To evaluate the clinical efficacy and systemic safety profile of conbercept in clinical practice on vascular endothelial growth factor(VEGF)-A,VEGF-B,and placental growth factor(PLGF)levels after intravitreal injections for the neovascular age-related macular degeneration(AMD).METHODS:Thir ty-five patients(35 eyes)with neovascular AMD received intravitreal injections of conbercept treatment with pro re nata protocol.Bestcorrected visual acuity(BCVA)and central retinal thickness(CRT)were detected before the intravitreal injection and at 1,3,and 12mo after conbercept treatment.The levels of serum VEGF-A,VEGF-B,and PLGF were measured by enzyme-linked immunosorbent assay before the injection and 1 and 12mo after conbercept treatments.RESULTS:At baseline,the mean BCVA score was 39.89±14.64 letters.The mean BCVA scores were 51.03±15.78,56.71±14.38,and 52.49±10.16 letters at 1,3,and 12mo after conbercept treatment,and the BCVA improvements were all significant,respectively(P<0.05).At baseline,the mean CRT was 436.7±141.9μm.At 1,3,and 12mo after conbercept treatment,the mean CRT values were 335.1±147.8,301.1±116.5,and 312.2±98.22μm,and the CRT improvements were all significant,respectively(P<0.05).At baseline,1 and 12mo after conbercept treatment,the mean levels of serum VEGF-A were 1013.8±454.3,953.1±426.4,and 981.5±471.7 pg/mL,the mean levels of serum VEGF-B were 46.93±24.76,42.99±19.16,and 45.32±18.76 pg/mL,the mean levels of serum PLGF at these points were 251.7±154.9,241.3±166.7,and 245.6±147.2 pg/mL,respectively.Compared with the baseline,the levels of serum VEGF-A,VEGF-B,and PLGF did not significantly change at 1 and 12mo after conbercept treatment,respectively(P>0.05).CONCLUSION:Conbercept intravitreal injection leads to BCVA and CRT improvement,however,it does not significantly affect systemic serum VEGF-A,VEGF-B,and PLGF levels at 1 and 12mo after intravitreal injection treating neovascular AMD.

关 键 词：conbercept vascular endothelial growth factor placental growth factor age-related macular degeneration 

分 类 号：R774.5[医药卫生—眼科]